FOLH1 and posterior cortical atrophy: In addition, [68Ga]Ga-PSMA-11 has the regulatory indication for selecting patients with metastatic castration-resistant PCa (mCRPC) for potential targeted radionuclide therapy with [177Lu]Lu-PSMA-617 (Pluvicto®, Novartis AG, Basel, Switzerland).